NASDAQ:TCON - TRACON Pharmaceuticals Stock Price, Forecast & News

TRACON Pharmaceuticals trades on the NASDAQ under the ticker symbol "TCON."

TRACON Pharmaceuticals Inc (NASDAQ:TCON) issued its quarterly earnings data on Tuesday, November, 5th. The biopharmaceutical company reported ($0.17) EPS for the quarter, topping analysts' consensus estimates of ($0.20) by $0.03. View TRACON Pharmaceuticals' Earnings History.

TRACON Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for TRACON Pharmaceuticals.

3 equities research analysts have issued twelve-month price objectives for TRACON Pharmaceuticals' shares. Their forecasts range from $7.00 to $18.00. On average, they expect TRACON Pharmaceuticals' share price to reach $12.50 in the next twelve months. This suggests a possible upside of 217.3% from the stock's current price. View Analyst Price Targets for TRACON Pharmaceuticals.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TRACON Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TRACON Pharmaceuticals.

Media coverage about TCON stock has trended somewhat negative recently, according to InfoTrie. The research firm scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. TRACON Pharmaceuticals earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for TRACON Pharmaceuticals.

TRACON Pharmaceuticals saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 54,800 shares, an increase of 218.6% from the December 31st total of 17,200 shares. Based on an average daily trading volume, of 261,800 shares, the short-interest ratio is presently 0.2 days. Approximately 1.9% of the company's shares are short sold. View TRACON Pharmaceuticals' Current Options Chain.

Some companies that are related to TRACON Pharmaceuticals include Idera Pharmaceuticals (IDRA), Organovo (ONVO), Neon Therapeutics (NTGN), Entera Bio (ENTX), BioCardia (BCDA), Outlook Therapeutics (OTLK), Vaxart (VXRT), aTyr Pharma (LIFE), CytRx (CYTR), Genetic Technologies (GENE), Titan Pharmaceuticals (TTNP), Aevi Genomic Medicine (GNMX), Vical (VICL), TrovaGene (TROV) and Enzon Pharmaceuticals (ENZN).

Based on aggregate information from My MarketBeat watchlists, some companies that other TRACON Pharmaceuticals investors own include Verastem (VSTM), SCYNEXIS (SCYX), Synergy Pharmaceuticals (SGYP), Opko Health (OPK), Progenics Pharmaceuticals (PGNX), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), MEI Pharma (MEIP), Melinta Therapeutics (MLNT) and Novavax (NVAX).

(TCON) raised $47 million in an initial public offering on Friday, January 30th 2015. The company issued 3,600,000 shares at $12.00-$14.00 per share. Wells Fargo Securities and Stifel served as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers.

TRACON Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include NEA Management Company LLC (11.04%). Company insiders that own TRACON Pharmaceuticals stock include Charles Theuer, Cross-Border Opportu Puissance, Enterprise Associates 14 New and Mark C Wiggins. View Institutional Ownership Trends for TRACON Pharmaceuticals.

TCON stock was sold by a variety of institutional investors in the last quarter, including NEA Management Company LLC. View Insider Buying and Selling for TRACON Pharmaceuticals.

Shares of TCON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TCON stock can currently be purchased for approximately $3.94.

TRACON Pharmaceuticals has a market capitalization of $12.37 million and generates $3 million in revenue each year. The biopharmaceutical company earns $-34,960,000.00 in net income (profit) each year or ($13.00) on an earnings per share basis. TRACON Pharmaceuticals employs 26 workers across the globe.View Additional Information About TRACON Pharmaceuticals.

The official website for TRACON Pharmaceuticals is http://www.traconpharma.com/.

TRACON Pharmaceuticals' mailing address is 4350 LA JOLLA VILLAGE DRIVE SUITE 800, San Diego CA, 92122. The biopharmaceutical company can be reached via phone at 858-550-0780 or via email at [email protected]